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1. INTRODUCTION {#dom13211-sec-0001}
===============

Tofogliflozin is a potent and highly selective sodium‐glucose co‐transporter‐2 (SGLT2) inhibitor that promotes urinary glucose excretion and controls hyperglycaemia in rodents, without causing hypoglycaemia, as well as improving hyperglycaemia and reducing body weight (BW) in clinical studies.[1](#dom13211-bib-0001){ref-type="ref"} The efficacy of SGLT2 inhibitors, alone or combined with dipeptidyl peptidase‐4 (DPP‐4) inhibitors, has recently been examined in several studies.[2](#dom13211-bib-0002){ref-type="ref"}, [3](#dom13211-bib-0003){ref-type="ref"}, [4](#dom13211-bib-0004){ref-type="ref"} Prescription of SGLT2 inhibitors is increasing, and clinical investigation of a combination drug is ongoing,[2](#dom13211-bib-0002){ref-type="ref"}, [3](#dom13211-bib-0003){ref-type="ref"} so combined use of SGLT2 inhibitors with DPP‐4 inhibitors is expected to become more frequent. SGLT2 inhibitors have the potential to satisfy the unmet need for weight control in patients with diabetes. These drugs reduce BW through calorie loss via renal glucose excretion and increased lipolysis in adipose tissue, and may be useful for obese patients with type 2 diabetes mellitus (T2DM) and insulin resistance; however, few investigations have assessed whether SGLT2 inhibitors improve insulin resistance in patients with T2DM or explored the relationship between changes in insulin resistance and body composition variables.[5](#dom13211-bib-0005){ref-type="ref"}

The aim of the present study, therefore was to study the effect of combined therapy with tofogliflozin and a DPP‐4 inhibitor on insulin sensitivity (glucose infusion rate \[GIR\]) in patients with T2DM, including the relationship between changes in insulin sensitivity and body composition.

2. METHODS {#dom13211-sec-0002}
==========

2.1. Study design and participants {#dom13211-sec-0003}
----------------------------------

This single‐arm, single‐centre, randomized, open‐label study was registered with the University Hospital Medical Information Network Clinical Trials Registry (no.: UMIN000014425).

The participants were 16 patients with T2DM, receiving treatment with a DPP‐4 inhibitor, who gave written informed consent, satisfied all of the inclusion criteria, and did not meet any of the exclusion criteria. Body composition and laboratory variables were compared between before administration of tofogliflozin (20 mg once daily) and after its administration for 12 weeks.

The 4‐dimensional impedance method (T‐Scan Plus) was used to measure body composition variables. The impact of tofogliflozin on peripheral glucose uptake (M value and M/I ratio) was determined using the hyperinsulinaemic‐euglycaemic clamp method.

2.2. Clinical laboratory tests {#dom13211-sec-0004}
------------------------------

Fasting blood and urine samples were collected at each visit for laboratory tests. In weeks 0 and 12, samples were collected before administration of tofogliflozin and performance of the clamp test. Most measurements were carried out by LSI Medience Corporation (Tokyo, Japan) using standard methods.

2.3. Hyperinsulinaemic‐euglycaemic clamp {#dom13211-sec-0005}
----------------------------------------

The peripheral glucose uptake rate was assessed using the combined hyperinsulinaemic‐euglycaemic clamp technique, as reported elsewhere.[6](#dom13211-bib-0006){ref-type="ref"} The clamp test was performed in weeks 0 and 12. Both the insulin infusion rate and the GIR were controlled by an artificial pancreas (STG‐55; Nikkiso Co., Ltd., Shizuoka, Japan).[7](#dom13211-bib-0007){ref-type="ref"} The plasma glucose level was determined at 1‐minute intervals during the clamp test using the continuous glucose monitoring system of the artificial pancreas, with a blood sampling rate of 2 mL/h. A hyperinsulinaemic state was achieved by primed‐constant infusion of insulin at 2.58 mU/kg/min (17.9 pmol/kg/min), corresponding to \~100 mU/m^2^/min (695 pmol/m^2^/min).

After the GIR became stable, the mean steady‐state GIR for a 30‐minute period was determined as an index of peripheral glucose uptake. Blood samples were collected before and after the start of insulin infusion to measure plasma glucose and insulin concentrations. The real rate of tissue glucose uptake during the insulin clamp test (M value) was calculated by subtracting urinary glucose excretion from glucose disposal to determine insulin‐mediated tissue glucose uptake.[5](#dom13211-bib-0005){ref-type="ref"}

2.4. Statistical analysis {#dom13211-sec-0006}
-------------------------

The M value and M/I ratio were compared between before and after tofogliflozin treatment using the paired *t* test. Pearson\'s correlation coefficient analysis was used to assess associations between changes in the M value and changes in body composition or laboratory variables. All reported *P* values are two‐sided. Analyses were performed using SAS version 9.4 (SAS Institute, Cary, North Carolina).

3. RESULTS {#dom13211-sec-0007}
==========

Of the 16 patients with T2DM receiving basal DPP‐4 inhibitor therapy who were candidates for 12 weeks of add‐on tofogliflozin in this study, 2 were excluded at screening (Table [S1](#dom13211-supitem-0002){ref-type="supplementary-material"}).

Table [1](#dom13211-tbl-0001){ref-type="table-wrap"} lists the laboratory variables that were measured at baseline and week 12 of add‐on tofogliflozin treatment. The M value, an index of insulin resistance, showed a significant increase of 0.90 ± 1.28 in week 12 (*P \<* .05). The M/I ratio also showed a significant increase of 0.49 ± 0.60 (*P \<* .05).

###### 

Insulin sensitivity and laboratory variables before and after add‐on tofogliflozin therapy

                                      N    Baseline         12 weeks          Change
  ----------------------------------- ---- ---------------- ----------------- ----------------------------------------------------------
  Insulin sensitivity (M value)       13   4.85 ± 1.46      5.75 ± 1.22       0.90 ± 1.28[\*](#dom13211-note-0004){ref-type="fn"}
  M/I ratio                           12   2.32 ± 0.94      2.81 ± 0.85       0.49 ± 0.60[\*](#dom13211-note-0004){ref-type="fn"}
  HbA1c, %                            14   8.24 ± 0.75      7.19 ± 0.67       −1.05 ± 0.47[\*\*\*](#dom13211-note-1005){ref-type="fn"}
  Fasting plasma glucose, mmol/L      14   10.12 ± 1.60     7.95 ± 0.99       −2.17 ± 1.70[\*\*\*](#dom13211-note-1005){ref-type="fn"}
  Insulin, pmol/L                     14   61.74 ± 21.46    64.17 ± 28.06     2.43 ± 14.24
  Glycoalbumin, %                     14   21.67 ± 3.12     17.46 ± 2.25      −4.21 ± 2.07[\*\*\*](#dom13211-note-1005){ref-type="fn"}
  HOMA‐IR                             14   4.01 ± 1.55      3.31 ± 1.63       −0.71 ± 1.46
  HOMA‐β                              14   28.66 ± 15.37    42.01 ± 15.67     13.35 ± 9.33[\*\*\*](#dom13211-note-1005){ref-type="fn"}
  QUICKI                              14   0.30 ± 0.00      0.31 ± 0.03       0.01 ± 0.03
  Total cholesterol, mmol/L           14   4.89 ± 0.87      4.90 ± 0.80       0.01 ± 0.50
  LDL cholesterol, mmol/L             14   2.67 ± 0.82      2.69 ± 0.93       0.02 ± 0.70
  HDL cholesterol, mmol/L             14   1.25 ± 0.30      1.35 ± 0.31       0.09 ± 0.15[\*](#dom13211-note-0004){ref-type="fn"}
  Triglycerides, mmol/L               14   2.10 ± 1.64      1.88 ± 2.14       −0.22 ± 1.27
  Non‐HDL‐cholesterol, mmol/L         14   3.63 ± 1.01      3.55 ± 0.99       −0.08 ± 0.41
  Adiponectin, mg/L                   14   7.24 ± 3.84      7.69 ± 3.63       0.45 ± 1.15
  IL‐6, ng/L                          14   1.30 ± 0.57      1.29 ± 0.61       −0.01 ± 0.62
  TNF‐α, ng/L                         14   1.48 ± 0.32      1.68 ± 0.61       0.20 ± 0.58[\*\*\*](#dom13211-note-1005){ref-type="fn"}
  hsCRP, mg/L                         14   0.90 ± 1.25      0.60 ± 0.51       −0.30 ± 1.30
  C‐peptide, nmol/L                   14   0.62 ± 0.13      0.65 ± 0.22       0.03 ± 0.13
  Glucagon (RIA), pmol/L              14   38.86 ± 9.33     38.82 ± 8.74      −0.04 ± 6.95
  Glucagon (sandwich ELISA), pmol/L   14   17.58 ± 8.07     17.96 ± 8.60      0.38 ± 4.63
  Active GLP‐1, pmol/L                14   6.54 ± 4.22      6.38 ± 3.58       −0.17 ± 3.71
  Blood ketone bodies, μmol/L         14   200.00 ± 96.08   290.00 ± 177.44   90.00 ± 177.44
  AST, IU/L                           14   23.43 ± 9.91     20.36 ± 6.22      −3.07 ± 5.41
  ALT, IU/L                           14   31.43 ± 16.22    22.86 ± 8.46      −8.57 ± 10.95[\*](#dom13211-note-0004){ref-type="fn"}
  ALP, IU/L                           14   215.93 ± 40.82   199.64 ± 44.22    −16.29 ± 37.63
  γ‐GTP, IU/L                         14   56.07 ± 54.32    38.14 ± 27.74     −17.93 ± 27.09[\*](#dom13211-note-0004){ref-type="fn"}
  SCr, μmol/L                         14   56.32 ± 12.64    57.08 ± 13.01     0.76 ± 5.71
  eGFR, mL/min/1.73 m^2^              14   92.71 ± 15.67    91.11 ± 13.92     −1.61 ± 8.36

Abbreviations: ALP, alkaline phosphatase; ALT, alanine aminotransferase; AST, aspartate aminotransferase; eGFR, estimated glomerular filtration rate; ELISA, enzyme‐linked immunosorbent assay; γ‐GTP, γ‐glutamyl transpeptidase; GLP‐1, glucagon‐like peptide 1; HbA1c, glycated haemoglobin; HOMA‐IR, homeostasis model assessment of insulin resistance; HOMA‐β, homeostasis model assessment of β‐cell function; hsCRP, high‐sensitivity C‐reactive protein; IL‐6, interleukin‐6; QUICKI, quantitative insulin sensitivity check index; RIA, radioimmunoassay; SCr, serum creatinine; TNF‐α, tumour necrosis factor‐α.

Data are presented as the mean ± SD.

*P \<* .05,

*P \<* .01,

*P \<* .001 vs baseline (one‐sample *t* test).

Two patients were excluded at screening. One patient was excluded from M value analysis because of failure to fast before blood collection, leaving 13 patients. This patient was also excluded from analysis of the M/I ratio along with another patient due to hemolysis of the blood sample, leaving 12 patients.

Furthermore, there was significant improvement in the following markers of glucose metabolism; glycated haemoglobin decreased by 1.05 ± 0.47%, fasting plasma glucose decreased by 2.17 ± 1.70 mmol/L, glycoalbumin decreased by 4.21 ± 2.07% and homeostasis model assessment of β‐cell function index increased by 13.35 ± 9.33 (all *P \<* .001). There was no significant change in glucagon level (−0.04 ± 6.95 pmol/L \[Sceti Medical Labo, Tokyo, Japan\] or 0.38 ± 4.63 pmol/L \[Cosmic Corporation, Tokyo, Japan\]), and no significant change in either glucagon‐like peptide‐1 or blood ketone levels.

Liver function tests showed significant improvement, with alanine aminotransferase decreasing by 8.57 ± 10.95 IU/L (*P \<* .05) and γ‐glutamyl transpeptidase declining by 17.93 ± 27.09 IU/L (*P \<* .05).

Among serum lipid levels, HDL cholesterol showed a significant increase of 0.09 ± 0.15 mmol/L (*P \<* .05).

Among inflammatory markers, there was a significant increase in tumour necrosis factor‐α by 0.20 ± 0.58 ng/L (from 1.48 ± 0.32 to 1.68 ± 0.61 ng/L; *P \<* .001).

Significant weight loss and reduction of body mass index were observed after 12 weeks of add‐on tofogliflozin treatment, with BW decreasing by 2.87 ± 1.48 kg (*P \<* .001) and body mass index declining by 1.11 ± 0.57 kg/m^2^ (*P \<* .001). Body composition variables generally showed significant decreases, including reduction of body fat mass by 1.33 ± 0.99 kg, lean body mass by 1.54 ± 0.77 kg, body water mass by 1.11 ± 0.55 kg, and muscle mass by 1.37 ± 0.72 kg (all *P \<* .001).

Comparing the M value and body composition variables, there was a significant negative correlation between changes in the M value and body fat mass (*r* = −0.67, *P* = .012; Table [2](#dom13211-tbl-0002){ref-type="table-wrap"}), but there was no correlation with the decrease in muscle mass or body water mass. Regarding adverse events, five patients (31.3%) reported pollakiuria and one patient (6.3%) had a urinary tract infection, but sexually transmitted infections, hypoglycaemia, ketosis and pancreatitis were not observed.

###### 

Relationships between changes in the M value and body composition variables

                                                Correlation coefficient   *P*
  --------------------------------------------- ------------------------- -----------------------------------------------
  Δ Body weight                                 −0.64                     .0187[\*](#dom13211-note-0006){ref-type="fn"}
  Δ Body mass index                             −0.63                     .0208[\*](#dom13211-note-0006){ref-type="fn"}
  Δ Waist circumference                         −0.67                     .0128[\*](#dom13211-note-0006){ref-type="fn"}
  Δ Body fat percentage                         −0.61                     .0267[\*](#dom13211-note-0006){ref-type="fn"}
  Δ Lean body mass                              −0.37                     .2143
  Δ Body fat mass                               −0.67                     .0122[\*](#dom13211-note-0006){ref-type="fn"}
  Δ Body water mass                             −0.37                     .2199
  Δ Intracellular water                         −0.17                     .5771
  Δ Extracellular water                         0.00                      .9900
  Δ Visceral/subcutaneous fat ratio             −0.52                     .0693
  Δ Muscle mass                                 −0.34                     .2619
  Δ Extracellular water/body water mass ratio   0.10                      .7507

*P \<* .05.

4. DISCUSSION {#dom13211-sec-0008}
=============

Both basic and clinical studies have shown that insulin resistance is improved by the direct hypoglycaemic effect of SGLT2 inhibitors, as well as by alleviation of glucotoxicity and weight loss (reduction of BW and body fat)[1](#dom13211-bib-0001){ref-type="ref"}, [8](#dom13211-bib-0008){ref-type="ref"}, [9](#dom13211-bib-0009){ref-type="ref"}, [10](#dom13211-bib-0010){ref-type="ref"}, [11](#dom13211-bib-0011){ref-type="ref"}; thus, it is clinically important to evaluate insulin resistance during SGLT2 inhibitor treatment.

In pair‐fed mice with or without tofogliflozin treatment for 8 weeks, the hyperinsulinaemic‐euglycaemic clamp test showed a significant increase in GIR in the tofogliflozin group and improvement in systemic insulin resistance, with muscle glucose uptake also increasing significantly in the tofogliflozin group, indicating a decrease in fat stores and improvement in peripheral insulin resistance.[11](#dom13211-bib-0011){ref-type="ref"} In the present study, the M value and M/I ratio both increased significantly (*P \<* .05) in patients receiving add‐on tofogliflozin therapy. There was a significant negative correlation between changes in the M value and body fat mass (*r* = −0.67, *P* = .012; Figure [S1](#dom13211-supitem-0001){ref-type="supplementary-material"}), but no correlation of the M value with the decrease in muscle mass, suggesting that alteration of muscle mass had a negligible influence on insulin resistance.

Only a few studies have evaluated the mechanism by which SGLT2 inhibitors improve insulin resistance in patients with T2DM.[5](#dom13211-bib-0005){ref-type="ref"} DeFronzo et al.[6](#dom13211-bib-0006){ref-type="ref"} performed a glucose clamp test in 18 patients with T2DM after 2 weeks of SGLT2 inhibitor or placebo administration. They found a significant increase in muscle glucose uptake in the SGLT2 inhibitor group, suggesting improvement in peripheral insulin resistance. In the present study, we evaluated insulin resistance by the hyperinsulinaemic‐euglycaemic clamp method and observed significant improvement in the M value and M/I ratio (*P \<* .05), along with a significant decrease in body fat mass. There was a negative correlation between the decrease in body fat mass and improvement in the M value, indicating that reduction of body fat was related to elevation of muscle glucose uptake by add‐on tofogliflozin therapy.

The present study assessed the add‐on effect of tofogliflozin in patients with T2DM who were refractory to DPP‐4 inhibitors, but the changes detected were similar to those previously reported in patients on tofogliflozin monotherapy. In previous studies performed in humans and mice, improvement in systemic insulin resistance has generally been observed despite elevation of endogenous glycogenesis.[5](#dom13211-bib-0005){ref-type="ref"}, [11](#dom13211-bib-0011){ref-type="ref"} Increased glycogenesis is believed to occur secondary to an increase in the glucagon/insulin ratio, rather than being attributable to exacerbation of hepatic insulin resistance.[5](#dom13211-bib-0005){ref-type="ref"} DPP‐4 inhibitors reduce endogenous glucose production through promotion of insulin secretion by β cells and suppression of glucagon secretion by α cells.[12](#dom13211-bib-0012){ref-type="ref"}, [13](#dom13211-bib-0013){ref-type="ref"} Two recent studies revealed reduction of the glucagon level after combined therapy with an SGLT2 inhibitor and a DPP‐4 inhibitor.[14](#dom13211-bib-0014){ref-type="ref"}, [15](#dom13211-bib-0015){ref-type="ref"} Glucagon has multiple effects on cardiac function,[16](#dom13211-bib-0016){ref-type="ref"} and a large‐scale clinical trial showed a decrease in cardiovascular mortality and hospitalization for heart failure after treatment with empagliflozin.[17](#dom13211-bib-0017){ref-type="ref"} In the present study, glucagon did not increase after initiation of add‐on SGLT2 inhibitor therapy in patients with T2DM already using DPP‐4 inhibitors. The absence of an increase in the glucagon/insulin ratio might have prevented elevation of endogenous glucose production, but it was not evaluated in the present study and further investigation is warranted. Combining a DPP‐4 inhibitor with an SGLT2 inhibitor seems to be a reasonable therapeutic option because glycaemic control is improved while elevation of glucagon is suppressed.

The limitations of the present study were the lack of a placebo group and the small number of participants (because of the burden of the clamp test); however, our results are consistent with those of a previous clinical study in terms of the main effects of tofogliflozin on BW and blood glucose. Further investigation will be required to better define the influence on body composition variables when an SGLT2 inhibitor is added to a DPP‐4 inhibitor.

In conclusion, glucose clamp studies showed an increase in peripheral glucose uptake (by muscle and fat) and reduction of body fat mass when tofogliflozin was added to basal therapy with a DPP‐4 inhibitor.
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**Figure S1.** Correlation between the changes in body fat mass and insulin sensitivity (M value).
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**Table S1.** Demographic and clinical profile of the subjects at baseline
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